Clinical Trial: NCT05064319
Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Medical University of South Carolina |
| Information Provided By: | Medical University of South Carolina |
| Last Update Posted: | 2026-09-09 |
Study Overview
Brief Summary
This research study evaluates the effects of an FDA-approved medication Gabapentin in individuals with Bipolar Disorder who smoke marijuana. Participants in the study will will be assigned to take either Gabapentin or a matched placebo. Study medication will be taken for 17 days. There will be 5 study visits, with 2 MRI brain imaging scans completed. Questionnaires and clinical interview measures will be completed at study visits along with consistent assessment of potential side effects from study medication.
Official Title
Conditions
Intervention / Treatment
- Drug: Gabapentin
- Drug: Placebo
Other Study ID Numbers
- 00112593
- R01DA054275
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Medical University of South Carolina |
| Information Provided By: | Medical University of South Carolina |
| Last Update Posted: | 2026-09-09 |
Study Overview
Brief Summary
This research study evaluates the effects of an FDA-approved medication Gabapentin in individuals with Bipolar Disorder who smoke marijuana. Participants in the study will will be assigned to take either Gabapentin or a matched placebo. Study medication will be taken for 17 days. There will be 5 study visits, with 2 MRI brain imaging scans completed. Questionnaires and clinical interview measures will be completed at study visits along with consistent assessment of potential side effects from study medication.
Official Title
Conditions
Intervention / Treatment
- Drug: Gabapentin
- Drug: Placebo
Other Study ID Numbers
- 00112593
- R01DA054275